Pharmacology and clinical toxicity of 4′-iodo-4′-deoxydoxorubicin: An example of successful application of pharmacokinetics to dose escalation in phase I trials

Journal of the National Cancer Institute

Volumn 82, Issue 6, 1990, Pages 469-477

  Gianni, Luca ^a   Viganò, Lucia ^a   Surbone, Antonella ^a   Ballinari, Dario ^b   Casali, Paolo ^a   Tarella, Corrado ^c   Collins, Jerry M ^d   Bonadonna, Gianni ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b PFIZER INC   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' IODOESORUBICIN; DRUG METABOLITE;

ARTICLE; BLOOD LEVEL; CARCINOMA; CLINICAL ARTICLE; DRUG METABOLISM; DRUG MONITORING; DRUG TOLERANCE; GRANULOCYTOPENIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; BLOOD PROTEINS; CARCINOMA; CHEMISTRY; COLONY-FORMING UNITS ASSAY; DOXORUBICIN; DRUG EVALUATION; HEMATOPOIESIS; HUMAN; MIDDLE AGE; NEOPLASM METASTASIS; PROSPECTIVE STUDIES; PROTEIN BINDING; SUPPORT, NON-U.S. GOV'T;

EID: 0025236690     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/82.6.469     Document Type: Article

References (31)

1. Collins JM, Zaharko DS, Dedrjck RL, et al: Potential roles for preclinical pharmacology in phase I trials. Cancer Treat Rep 70:73–80, 1986
2. eortc Pharmacokinetics and Metabolism group: Pharmacokinetically guided dose escalation in phase I trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23:1083–1087, 1987
3. Coluns JM: Pharmacology and drug development. J Natl Cancer Inst 80:790–793, 1988
4. Davis LE, Alberts DS, Plezia PM, et al: Predictive model for plasma concentration-versus-time profiles of investigational anticancer drugs in patients. J Natl Cancer Inst 80:815–818, 1988
5. Barbieri B, Giuliani FC, Bordoni T, et al: Chemical and biological characterization of 4’-iodo-4’-deoxydoxorubicin. Cancer Res 47:4001–4006, 1987
6. Goldsmith MA, Slavik M, Carter SK: Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res 35:1354–1364, 1975
7. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207–214, 1981
8. Gianni L, Viganò L, Lanzi C, et al: Role of daunosamine and hydroxyacetyl side chain in reaction with iron and lipid peroxidation by anthracyclines. J Natl Cancer Inst 80:1104–1111, 1988
9. Robert J: Extraction of anthracyclines from biological fluids for HPLC evaluation. J Liquid Chromatogr 3:1561–1572, 1980
10. Gibaldi M, Perrier D: Appendix D estimation of areas. In Pharmacokinetics (Swarbrick J, ed). New York: Marcel Dekker, 1982, pp 445–449
11. Benet LZ, Galeazzi RL: Noncompartmental determination of the steady state volume of distribution. J Pharm Sci 68:1071–1074, 1979
12. Kaplan L, Lee S-C, Levine L: Partial purification and some properties of human erythrocyte prostaglandin 9-ketoreductase and 15-hydroxypros-taglandin dehydrogenase. Arch Biochem Biophys 167:287–293, 1975
13. Ahmed NK, Felsted RL, Bachur NR: Heterogeneity of anthracycline antibiotic carbonyl reductase in mammalian livers. Biochem Pharmacol 27:2713–2719, 1978
14. Loveless H, Arena E, Felsted RL, et al: Comparative mammalian metabolism of Adriamycin and daunorubicin. Cancer Res 38:593–598, 1978
15. Lanfrancone L, Ferrero D, Gallo E, et al: Release of hemopoietic factors by human T cell lines with either suppressor or helper activity. J Cell Physiol 122:7–13, 1985
16. Dessypris EN, Brenner DE, Hande KR: Toxicity of doxorubicin metabolites to human marrow erythroid and myeloid progenitors in vivo. Cancer Treat Rep 70:487–490, 1986
17. Formelli F, Carsana R, Pollini C: Pharmacokinetics of 4’-deoxy-4’-iodo-doxorubicin in plasma and tissues of tumor-bearing mice compared with doxorubicin. Cancer Res 47:5401–5406, 1987
18. Huffman DH, Bachur NR: Daunorubicin metabolism by human hematological components. Cancer Res 32:600–605, 1972
19. Rahman A, Goodman A, Foo W, et al: Clinical pharmacology of daunorubicin in phase I patients with solid tumors: Development of an analytical methodology for daunorubicin and its metabolites. Semin Oncol 11:36–44, 1984
20. Bonadonna G, Monfardlvi S, DeLena M, et al: Phase I and preliminary phase II of adriamycin (NSC 123127). Cancer Res 30:2572–2582, 1970
21. Bonfante V, Villani F, Bonadonna G: Toxic and therapeutic activity of 4’-epi-doxorubicin. Tumori 68:105–111, 1982
22. Ferrari L, Rossi A, Brambilla C, et al: Phase I study of 4’-deoxydoxo-rubicin. Invest New Drugs 2:287–295, 1984
23. Bonfante V, Ferrari L, Villani F, et al: Phase 1 study of 4-demethoxy-daunorubicin. Invest New Drugs 1:161–168, 1983
24. Wheeler RH, Ensminger WD, Thrall JH, et al: High-dose doxorubicin: An exploration of the dose-response curve in human neoplasia. Cancer Treat Rep 66:493–498, 1982
25. Greene RF, Collins JM, Jenkins JF, et al: Plasma pharmacokinetics of Adriamycin and adriamycinol: Implications for the design on in vitro experiments and treatment protocols. Cancer Res 43:3417–3421, 1983
26. Speth PA, van de Loo FA, Linssen PC, et al: Plasma and human leukemic cell pharmacokinetics of ora! and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 40:643–649, 1986
27. Bronchud M, Margison J, Matthews H, et al: Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer using G-CSF to prevent haematological toxicity. Proc ASCO 8:311–380, 1989
28. Lu K, Savaraj N, Kavanagh J, et al: Clinical pharmacology of 4-demethoxydaunorubicin (DMDR). Cancer Chemother Pharmacol 17: 143–148, 1986
29. Casazza AM, Barbieri B, Fumagalli A, et al: Biologic activity of 4-demethoxy-13-dihydrodaunorubicin. Proc Am Assoc Cancer Res 24:251, 1983
30. Zunino F, Gambetta RA, Zaccara A, et al: A differential interaction of doxorubicin and daunorubicin with human serum proteins. Tumori 67: 521–524, 1981
31. Ballinari D, Pezzoni G, Giuliani FC, et al: Biological profile of 13-OH-iododoxorubicin: Preclinical data. Proc Am Assoc Cancer Res 30: 482, 1989